

## CLAIMS

1. A composition, comprising 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate.
2. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ) exhibiting an X-ray powder diffraction pattern having characteristic reflexes (expressed in degrees of diffraction angle  $2\theta$ ) at approximately: 9.0, 10.0, 12.8, 15.9, 18.1, 18.8, 19.8, 20.1, 21.8, 23.7.
3. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ), characterized by an X-ray powder diffraction pattern shown in Figure 1.
4. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ), exhibiting an infrared spectrum recorded in attenuated total reflectance having characteristic absorption bands expressed in reciprocal centimeters at approximately: 3246, 1644, 1455, 1381, 1368, 1292, 1117, 1092, 1042, 743.
5. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ), characterized by a complete infrared spectrum shown in Figure 2.
6. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ), exhibiting a melting point at approximately 248°C.

7. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\alpha$ ), characterized by a complete differential scanning calorimeter trace shown in Figure 3.
8. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\beta$ ), exhibiting an X-ray powder diffraction pattern having characteristic reflexes (expressed in degrees of diffraction angle  $2\theta$ ) at approximately: 9.3, 11.6, 12.2, 17.6, 18.0, 18.6, 19.3, 20.8, 23.4, 26.5.
9. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\beta$ ), characterized by an X-ray powder diffraction pattern shown in Figure 4.
10. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\beta$ ), exhibiting an infrared spectrum recorded in attenuated total reflectance having characteristic absorption bands expressed in reciprocal centimeters at approximately: 3338, 3279, 1602, 1564, 1389, 1219, 1154, 1134, 1034, 732.
11. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\beta$ ), characterized by a complete infrared spectrum shown in Figure 5.
12. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\beta$ ), exhibiting a melting point at approximately 220°C.

13. The composition according to claim 1, wherein the 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate is in a polymorphic form ( $\beta$ ), characterized by a complete differential scanning calorimeter trace shown in Figure 6.
14. The composition of any one of claims 1-13, further comprising a pharmaceutically acceptable carrier.
15. The composition of claim 14, comprising an effective amount of 4-(4-*trans*-hydroxy-cyclohexyl)amino-2-phenyl-7*H*-pyrrolo[2,3d]pyrimidine hydrogen mesylate.
16. The composition of claim 15, in a parenteral dosage form.
17. A method for the treatment of a condition selected from the group consisting of essential hypertension, congestive heart failure and renal failure, comprising administering an effective amount of the composition according to any one of claims 1-13.